Remifentanil for gynaecological and obstetric procedures

Current Opinion in Anaesthesiology

Volumn 13, Issue 3, 2000, Pages 271-275

  Buerkle, Hartmut ^a   Wilhelm, Wolfram ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 METHOXYCARBONYL 4 (N PHENYLPROPIONAMIDO)PIPERIDINO]PROPIONIC ACID; ALFENTANIL; DESFLURANE; DIAZEPAM; DICLOFENAC; DIPYRONE; ESTERASE; FENTANYL; GLYCINE; ISOFLURANE; KETOROLAC; MIDAZOLAM; MU OPIATE RECEPTOR AGONIST; MUSCLE RELAXANT AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PETHIDINE; PIRITRAMIDE; PROPOFOL; REMIFENTANIL; SUFENTANIL;

ABDOMINAL HYSTERECTOMY; ANALGESIC ACTIVITY; ANESTHESIST; ANESTHETIC RECOVERY; ARTICLE; AWARENESS; BLOOD PLACENTA BARRIER; CESAREAN SECTION; CHOLECYSTECTOMY; CLINICAL PRACTICE; CLINICAL TRIAL; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; FEMALE; FERTILIZATION IN VITRO; GYNECOLOGIC SURGERY; HUMAN; INTRAOPERATIVE PERIOD; LAPAROSCOPIC SURGERY; MINIMUM LUNG ALVEOLUS CONCENTRATION; MUSCLE RIGIDITY; NAUSEA; OBSTETRIC OPERATION; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RESPIRATORY FUNCTION; UTERINE TUBE STERILIZATION; VOMITING;

EID: 0034123454     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200006000-00006     Document Type: Article

References (30)

1. 1 Rosow C. An overview of remifentanil. Anesth Analg 1999; 89 (Suppl 4):S1-S3.
2. 2 Feldman PL, James MK, Brackeen MF, Bilotta JM, Schuster SV, Lahey AP, et al. Design, synthesis, and pharmacological evaluation of ultrashort-to long-acting opioid analgetics. J Med Chem 1991; 34:2202-2208.
3. 3 Thompson R, Mansour A, Akil H, Watson S. Cloning and pharmacological characterization of a rat μ-opioid receptor. Neuron 1993; 11:903-913.
4. 4 Chen J, Mestek A, Liu J, Hurley J, Yu L. Molecular cloning and functional expression of a μ-opioid receptor from the rat brain. Mol Pharmacol 1993; 44:8-12.
5. 5 Bürkle H, Dunbar S, Van Aken H. Remifentanil: a novel, short-acting μ-opioid. Anesth Analg 1996; 83:646-651.
6. 6 Reves J. Educational considerations for the clinical introduction and use of remifentanil. Anesth Analg 1999; 89(Suppl 4):S4-S6.
7. 7 Glass S, Gan T, Howell S. A review of the pharmacokinetics and pharmacodynamics of remifentanil. Anesth Analg 1999; 89 (Suppl 4):S7-S14. One of the most comprehensive recent reviews of the pharmacology of remifentanil.
8. 8 Stiller RL, Davis PJ, McGowan FX, Scierka A, Gupta S, Muir K. In vitro metabolism of remifentanil: The effects of pseudocholinesterase deficiency. Anesthesiology 1995; 83:A381.
9. 9 Hoke JF, Cunningham F, James MK, Muir KT, Hoffman WE. Comparative pharmacokinetics and pharmacodynamics of remifentanil, its principle metabolite (GR90291) and alfentanil in dogs. J Pharmacol Exp Ther 1997; 281:226-232.
10. 10 Manullang J, Egan TD. Remifentanil's effect is not prolonged in a patient with pseudocholinesterase deficiency. Anesth Analg 1999; 89:529-530.
11. 11 Sebel PS, Hoke JF, Westmoreland C, Hug CJ, Muir KT, Szlam F. Histamine concentrations and hemodynamic responses after remifentanil. Anesth Analg 1995; 80:990-993.
12. 12 Jhaveri R, Joshi P, Batenhorst R, Baughman V, Glass PSA. Dose comparison of remifentanil and alfentanil for loss of consciousness. Anesthesiology 1997; 87:253-259.
13. 13 Murdoch JA, Hyde RA, Kenny GN. Target-controlled remifentanil in combination with propofol for spontaneously breathing day-case patients. Anaesthesia 1999; 54:1028-1031.
14. 14 Lauwers M, Camu F, Breivik H, Hagelberg A, Rosen M, Sneyd R, et al. The safety and effectiveness of remifentanil as an adjunct sedative for regional anesthesia. Anesth Analg 1999; 88:134-140. This study describes the use of remifentanil with Intravenous midazolam as an adjunct. Not surprisingly, respiratory depression was observed; therefore, careful surveillance of respiratory function is mandatory. However, remifentanil in combination with other sedatives or anaesthetics should not be recommended during regional anaesthetic techniques.
15. 15 Wilhelm W, Grüneß V, Kleinschmidt S, Larsen R. Remifentanil-based anaesthesia: theoretical considerations and practical recommendations. Anästhesiol Intensivmed 1998; 39:359-361. This is a comprehensive overview of the general considerations in using remifentanil.
16. 16 Suttner S, Boldt J, Schmidt C, Piper S, Kumle B. Cost analysis of target-controlled infusion-based anesthesia compared with standard anesthesia regimens. Anesth Analg 1999; 88:77-82. This very interesting study elucidated the daily costs of distinct anaesthetic regimens.
17. 17 Kovac AL, Azad SS, Steer P, Witkowski T, Batenhorst R, McNeal S. Remifentanil versus alfentanil in a balanced anesthetic technique for total abdominal hysterectomy. J Clin Anesth 1997; 9:532-541.
18. 18 Philip BK, Scuderi PE, Chung F, Conahan TJ, Maurer W, Angel JJ, et al. Remifentanil compared with alfentanil for ambulatory surgery using total intravenous anesthesia. The Remifentanil/Alfentanil Outpatient TIVA Group. Anesth Analg 1997; 84:515-521.
19. 19 Wilhelm W, Berg K, Langhammer A, Bauer C, Biedler A, Larsen R. A comparison of remifentanil based anaesthesia with desflurane or propofol for gynaecological laparoscopies. Anästhesiol Intensivmed Notfallmed Schmerzther 1998; 33:552-556.
20. 20 Johannsen EK, Munro AJ. Remifentanil in emergency caesarean section in pre-eclampsia complicated by thrombocytopenìa and abnormal liver function. Anaesth Intensive Care 1999; 27:527-529. This case report is notable because it reflects the indications of remifentanil in obstetrics: perfect haemodynamic control and end-organ-independent metabolism.
21. 21 Bedard JM, Richardson MG, Wissler RN. General anesthesia with remifentanil for Cesarean section in a parturient with an acoustic neuroma. Can J Anaesth 1999; 46:576-580.
22. 22 Scott H, Bateman C, Price M. The use of remifentanil in general anaesthesia for caesarean section in a patient with mitral valve disease. Anaesthesia 1998; 53:695-697.
23. 23 Kan RE, Hughes SC, Rosen MA, Kessin C, Preston PG, Lobo EP. Intravenous remifentanil: placental transfer, maternal and neonatal effects. Anesthesiology 1998; 88:1467-1474.
24. 24 Buerkle H, Yaksh TL. Continuous intrathecal administration of shortlasting mu opioids remifentanil and alfentanil in the rat. Anesthesiology 1996; 84:926-935.
25. 25 Buerkle H, Yaksh TL. Comparison of the spinal actions of the mu-opioid remifentanil with alfentanil and morphine in the rat. Anesthesiology 1996; 84:94-102.
26. 26 Wilhelm W, Biedler A, Hammadeh ME, Fieser R, Grüneß V. Remifentanil for oocyte retrieval: a new single-agent monitored anaesthesia care technique. Anaesthesist 1999; 48:698-704.
27. 27 Glass PS, Iselin-Chaves IA, Goodman D, Delong E, Hermann DJ. Determination of the potency of remifentanil compared with alfentanil using ventilatory depression as the measure of opioid effect. Anesthesiology 1999; 90:1556-1563. This excellent study was designed to compare the effects of opioids on ventilatory drive in volunteers.
28. 28 Litman RS. Conscious sedation with remifentanil and midazolam during brief painful procedures in children. Arch Pediatr Adolesc Med 1999; 153:1085-1088.
29. 29 Hammadeh M, Wilhelm W, Huppert A, Rosenbaum P, Schmidt W. Effects of general anaesthesia vs. sedation on fertilization, cleavage and pregnancy rates in an IVF program. Arch Gynecol Obstet 1999; 263:56-59.
30. 30 Albrecht S, Schüttler J, Yarmush J. Postoperative pain management after intraoperative remifentanil. Anesth Analg 1999; 89 (Suppl 4):S40-S45.